Abstract library

1109 results for "clinical outcomes".
#2841 Novelties in Primary and Metastatic GEP-NENs Clinical Outcome Investigation
Introduction: Gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NENs) WHO classification, using strict cut-offs, should reflect their biological features. In real world, strict cut-offs not adequately segregate prognostic groups, in particular on metastasis (M).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Pathology - grading, staging
Presenting Author: MD, PhD Massimo Milione
#1773 Clinical Outcomes of Systemic Chemotherapy in Patients with High Grade Neuroendocrine Carcinoma of Biliary Tract
Introduction: : Neuroendocarine tumor of biliary tract is very rare and clinical outcomes of advanced neuroendocrine tumors of biliary tract has not been well demonstrated.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Medical treatment – Chemotherapy, medical treatment - others
Presenting Author: MD Changhoon Yoo
Authors: Yoo C, Lee K, Kim K P, Chang H M, ...
#2711 Gastric Neuroendocrine Neoplasms: Clinical Management and Outcomes in a Cohort of 54 Patients
Introduction: Gastric NENs are increasingly being diagnosed at endoscopy. The majority of these are type 1 gastric NEN. However, around 10-20% can be type 3 or type 4 Gastric NENs.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Surgical treatment and Ablative Therapies
Presenting Author: Alexandra Victor
Authors: Victor A, Ramage J, Cope J, Maclean R, ...
#513 Correlation Between mTOR Pathway and Clinical Outcomes in Patients with Well-Differentiated Neuroendocrine Tumors Treated with Everolimus
Introduction: Everolimus has been studied in preclinical and clinical settings, showing it to be active and effective. Tumors exhibiting the constitutively activated phosphatidylinositol-3-kinase-AKT-mTOR (PI3K/AKT/mTOR) pathway, are potentially susceptible to mTOR inhibitors. Even though Everolimus is both an antiproliferative and anti-angiogenic drug, we do not know the possible prognostic or predictive role of p-mTOR pathway.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Dr Francesca Spada
Authors: Spada F, Pisa E, Lorizzo K, Barberis M, ...
Keywords: mTOR
#592 Expression of PTEN and mTOR in Pancreatic Neuroendocrine Tumors and Their Clinical Significance
Introduction: mTOR is currently under investigation as a potential target for anticancer therapy. Loss of PTEN, the negative regulators of the PI3K-Akt-mTOR pathway, have been associated with cancer.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Xu Han
Authors: Han X, Ji Y, Zhao J, Xu X, ...
#2857 Clinical Epidemiology Study of Rectal Neuroendocrine Neoplasms in China: A National Multicenter 10-Year Retrospective Study
Introduction: Representative data on the rectal neuroendocrine neoplasms in Chinese patients is rare.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: professor Fan Jinhu
Authors: Jinhu F, Yihebali C, Huan Y, Su Z, ...
#1937 Clinical Features and Outcomes of Advanced PNETs Treated with Sunitinib: Data from CRIPNET-GETNE Study
Introduction: There are several effective drugs for advanced pancreatic neuroendocrine tumors (PNETs) but the right treatment sequence hasn’t been defined yet.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Medical treatment - Targeted therapies
Presenting Author: MD-PhD Paula Jimenez Fonseca
#2773 Impact on Outcome in Patients (pts) with Advanced Neuroendocrine Neoplasms (NENs) Included in Prospective Clinical Trials (CT)
Introduction: Access to CT offers cancer pts the opportunity to receive new treatments and better monitoring of efficacy and toxicity. The increase of systemic therapy options in advanced NENs has relegated the inclusion of pts in CT to later lines of treatment as suggested in most guidelines.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - others, not specified
Presenting Author: MD PhD Jorge Hernando-Cubero
#823 Association Between Tumor Expression of VEGFA, VEGFR1 (FLT1), VEGFR2 (KDR), and Clinical Outcomes in Neuroendocrine Tumors
Introduction: Clinical studies have suggested efficacy of VEGF pathway inhibitors in the treatment of advanced neuroendocrine tumors (NETs).
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Dr. Zhirong Qian
#2259 Clinical Characteristics, Treatment Outcomes and Potential Novel Therapeutic Options for Patients with Prostatic Neuroendocrine Carcinoma
Introduction: Prostatic neuroendocrine carcinomas (PNECs) are rare tumors with poor prognosis. While platinum and etoposide based chemotherapy regimens (PE) are commonly applied in first-line for advanced disease, clinical-grade evidence for treatment options in second-line and beyond is very limited.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Non digestive NETs (bronchial, thymic, others) - diagnosis and therapy
Presenting Author: Dr. med. Leonidas Apostolidis